Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Enrolling by invitation × Irinotecan × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Completed 44 Recruiting 21 Terminated 16 Unknown 9 Withdrawn 7 Active not recruiting 5 Not yet recruiting 3 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumors 1

Interventions

Lenalidomide 2 irinotecan sucrosofate 1 enzalutamide 1 Ruthenium-106 1 Radiotherapy 1 Melphalan 1 Mannitol 1 Leukocyte Count 1 Irinotecan 1 Folfox protocol 1 Dexamethasone 1 Cyclophosphamide 1 Carboplatin 1 Brachytherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05865925 2024-04-25

Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors

Luye Pharma Group Ltd.

Phase 1/2 Enrolling by invitation

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡